Optomed Oyj Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Juho Himberg

İcra Kurulu Başkanı

€64.0k

Toplam tazminat

CEO maaş yüzdesi	81.3%
CEO görev süresi	1.1yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	5.8yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Juho Himberg'un ücretlendirmesi Optomed Oyj'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-€6m
Jun 30 2024	n/a	n/a	-€5m
Mar 31 2024	n/a	n/a	-€4m
Dec 31 2023	€64k	€52k	-€4m

Tazminat ve Piyasa: Juho 'nin toplam tazminatı ($USD 67.05K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 472.15K ).

Tazminat ve Kazançlar: Juho şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Juho Himberg (54 yo)

1.1yrs

Görev süresi

€64,000

Tazminat

Mr. Juho Himberg is Chief Executive Officer of Optomed Oyj since October 1, 2023. He has served as the CEO of Aidian (former Orion Diagnostica), a leading point-of-care diagnostics company with innovative...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Juho Himberg	Chief Executive Officer	1.1yrs	€64.00k	Veri yok
Seppo Kopsala	Founder	20.8yrs	€156.00k	Veri yok
Sakari Knuutti	CFO, Chief Legal Officer & Secretary of the Board	5.8yrs	Veri yok	Veri yok

5.8yrs

Ortalama Görev Süresi

46yo

Ortalama Yaş

Deneyimli Yönetim: 36U0 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Seppo Makinen	Independent Director	5.8yrs	€19.00k	0.062% € 48.8k
Reijo Tauriainen	Independent Director	5.8yrs	€19.00k	0.078% € 61.1k
Catherine Calarco	Independent Director	1.5yrs	€19.00k	0.017% € 13.6k
Petri Salonen	Chairman of the Board	18.8yrs	€114.00k	0.083% € 64.7k
Ty Lee	Independent Director	1.5yrs	€19.00k	0.017% € 13.6k
Anna Tenstam	Independent Director	4.4yrs	€19.00k	0.037% € 28.8k
Robert Chang	Member of International Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Nina Hautala	Member of International Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Dan Milea	Member of International Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Tunde Peto	Member of International Scientific Advisory Board	3.8yrs	Veri yok	Veri yok
Daniel Ting	Member of International Scientific Advisory Board	3.8yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 36U0 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Optomed Oyj Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Optomed Oyj, Annual General Meeting, May 09, 2025

Optomed Oyj Announces Nomination Board

Optomed Oyj, Annual General Meeting, May 10, 2024

Optomed Announces CEO Transition Plan

Optomed Oyj Approves Board Changes

Mars Duan Has Notifies Optomed plc That He Is Not Available for Re-Election

Recent updates

Optomed plc Raises Earnings Guidance for the Full Year 2024

Optomed plc Raises Earnings Guidance for the Full Year 2024

No longer forecast to breakeven

Third quarter 2024 earnings released: €0.087 loss per share (vs €0.027 loss in 3Q 2023)

New minor risk - Profitability

No longer forecast to breakeven

New minor risk - Market cap size

Optomed Oyj, Annual General Meeting, May 09, 2025

Second quarter 2024 earnings released: €0.10 loss per share (vs €0.084 loss in 2Q 2023)

Optomed Oyj Reaffirms Revenue Guidance for the Year 2024

Optomed Oyj Provides Revenue Guidance for the Full Year 2024

Forecast to breakeven in 2026

First quarter 2024 earnings released: €0.064 loss per share (vs €0.076 loss in 1Q 2023)

Optomed Plc Announces Optomed Aurora with AEYE Receives U.S. Food & Drug Administration Clearance in US

Optomed USA, Inc. Introduces Optomed Aurora AEYE

Full year 2023 earnings released: €0.27 loss per share (vs €0.37 loss in FY 2022)

Optomed Oyj Provides Revenue Guidance for the Full Year 2024

Optomed Oyj Announces Nomination Board

Optomed Oyj Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings released: €0.027 loss per share (vs €0.097 loss in 3Q 2022)

New minor risk - Share price stability

Forecast breakeven date moved forward to 2024

Optomed Oyj has completed a Follow-on Equity Offering in the amount of €4.290413 million.

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.096 loss in 2Q 2022)

Optomed Oyj, Annual General Meeting, May 10, 2024

New minor risk - Share price stability

New minor risk - Share price stability

Forecast breakeven date pushed back to 2025

Optomed Announces CEO Transition Plan

Optomed Oyj Approves Board Changes

First quarter 2023 earnings released: €0.076 loss per share (vs €0.10 loss in 1Q 2022)

Optomed Plc Provides Revenue Guidance for the Full Year 2023

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: €0.37 loss per share (vs €0.32 loss in FY 2021)

Optomed Oyj Provides Revenue Guidance for the Full Year of 2023

Mars Duan Has Notifies Optomed plc That He Is Not Available for Re-Election

High number of new and inexperienced directors

Third quarter 2022 earnings released: €0.097 loss per share (vs €0.062 loss in 3Q 2021)

Optomed Oyj Updates Earnings Guidance for the Full Year 2022

Optomed Oyj Announces Board Appointments

Optomed plc Elects Mars Duan to the Board of Directors

Second quarter 2022 earnings released: €0.096 loss per share (vs €0.065 loss in 2Q 2021)

Optomed Oyj, Annual General Meeting, May 10, 2023

Optomed Plc Announces Resignation of Xisi Guo from Board of Directors, Effective August 19, 2022

Optomed Oyj Announces Resignation of Niina Huikuri as Vice President, Marketing and Member of the Leadership Team

Optomed Oyj Announces Executive Changes

High number of new and inexperienced directors

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş